ÇALIŞMA PROJELERİ
- Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin’s Lymphoma: Çok uluslu çalışma yardımcı araştırıcı, 2004
- “Multiple myelomda risk grupları ile P-glikoprotein ekspresyonu arasındaki ilişkinin belirlenmesi”, Türk Hematoloji Derneği, 2011-11, Proje Yürütücüsü, 2011.
- A Randomized, Open Label, Multi Centre Study To Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients with CD20 Diffuse Large B-Cell Lymphoma or CD20 Follicular Non Hodgkin’s Lymphoma Grades 1,2 or 3A, Çok uluslu çalışma sorumlu araştırıcı, 2014.
- A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (C14012), Çok uluslu çalışma yardımcı araştırıcı, 2015.
- A Randomized, Multicenter, Open Label , Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab in Subjects with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PCYC-1130-CA) Pharmacyclics, Çok uluslu çalışma sorumlu araştırıcı, 2015.
- Double-Blind Randomized Study To Compare The Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects with Relapsed/Refractory Indolent Lymphoma ( protokol number: CC5013-NHL-007), Çok uluslu çalışma sorumlu araştırıcı, 2015.
- A Multicenter, Open-Label, Single Arm, Phase IIIB, International Study Evaluating The Safety of Obinutuzumab Alone or In Combination with Chemoterapy In Patients with Previously Unreated or Relapsed/Refractory Chronic Lymphocytic Leukemia, Çok uluslu çalışma sorumlu araştırıcı, 2014.
- A Phase 3, Double Blind Randomized Study To Compare The Efficacy And Safety Of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo In Subjects With Relapsed/Refractory Indolent Lymphoma, (CC-5013-NHL-007), Çok uluslu çalışma sorumlu araştırıcı, 2016.
- A Phase 4, Open-Label, Single- Arm of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (C25006), Çok uluslu çalışma sorumlu araştırıcı, 2016.
- Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Compare The Efficacy and Safety of Lenolidomide (CC-5013) Plus R-CHOP Chemotherapy in Subjects with Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma (CC-5013-DLC-002), Çok uluslu çalışma sorumlu araştırıcı, 2016.
2017-12-05